Ara
Toplam kayıt 2, listelenen: 1-2
Gilteritinib (XOSPATA (R)) in Turkey: Early access program results
(Mattioli 1885, 2023)
Background And Objectives: Gilteritinib (XOSPATA (R), Astellas) is a type I oral FLT3 inhibitor, a tyrosine kinase AXL inhibitor, involved in both c-Kit and FMS-like tyrosine kinase 3 (FLT3) resistance. In the phase 3 ...
Charlson comorbidity index (CCI) in diffuse large B-cell lymphoma: A new approach in a multicenter study
(Springer, 2023)
Purpose: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of adult lymphomas. The incidence of DLBCL increases with age and has a fairly rapid fatal course without treatment. Patients often have difficulty ...